Pyridazinopyridone derivatives substituted with nitrogen-containing functional groups and their use

Pyridazinopyridone derivatives with nitrogen-containing functional groups are developed to address the gap in SOS1 inhibitors, offering therapeutic benefits in treating cancers and pathogenic diseases by effectively inhibiting SOS1 activity and enhancing MEK inhibitor efficacy.

JP2026520137APending Publication Date: 2026-06-22SICHUAN HUIYU PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
SICHUAN HUIYU PHARMA
Filing Date
2024-05-30
Publication Date
2026-06-22

AI Technical Summary

Technical Problem

Current SOS1 inhibitors are not sufficiently developed to meet clinical needs, and there is a lack of commercially available drugs targeting the SOS1 protein, which plays a crucial role in various cancers and pathogenic diseases.

Method used

Development of pyridazinopyridone derivatives substituted with nitrogen-containing functional groups that act as potent SOS1 inhibitors, including compounds represented by Formula I and their variants, to effectively inhibit SOS1 activity.

Benefits of technology

The pyridazinopyridone derivatives demonstrate potential as effective therapeutic agents for cancers and pathogenic diseases by inhibiting SOS1, enhancing the efficacy of MEK inhibitors, and providing a synergistic effect in treating conditions like non-small cell lung cancer, pancreatic cancer, ovarian cancer, and chronic myeloid leukemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026520137000001
    Figure 2026520137000001
  • Figure 2026520137000002
    Figure 2026520137000002
  • Figure 2026520137000003
    Figure 2026520137000003
Patent Text Reader

Abstract

This invention relates to the pharmaceutical technology, and more particularly to a pyridadinopyridone derivative substituted with a nitrogen-containing functional group for use as an SOS1 protein inhibitor, and its use. The compounds provided in this invention exhibit clear inhibitory activity against the SOS1 protein, can be used as SOS1 protein inhibitors, have excellent drug-forming potential, and can be used in the manufacture of therapeutic drugs for diseases such as cancer and pathogenic rash diseases mediated by the SOS1 protein, thus showing promising future applications.
Need to check novelty before this filing date? Find Prior Art